The biotech sector is seeing rapid innovation at the intersection of artificial intelligence (AI) and genomics. Advances include AI-powered molecular diagnostics, computational drug discovery, and digital pathology platforms with multi-modal data integration. Companies like Imagene AI and Chai Discovery are leveraging AI to revolutionize antibody development and precision medicine. Additionally, early detection tools using AI promise enhanced outcomes in oncology and rare disease management. These developments underscore a broader industry trend towards AI-driven biomedical insights and personalized therapeutics.